Natural Compound‐Rhein and PROTACs Unleash Potent VEGFR‐2 Degraders
Chemistry & Biodiversity · 2024
DOI: 10.1002/cbdv.202400753 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2024. Verfasst von Ziqing Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Engineering Research Centre of Molecular Medicine of Ministry of Education, Key Laboratory of Fujian Molecular Medicine, Key Laboratory of Precision …. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor Receptor-2, Biological Products, Apoptosis, Molecular Docking Simulation. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Fujian Provincial Industry-University Cooperation Project, Quanzhou High-Level Talent Innovation and Entrepreneurship Project, National Natural Science Foundation of China.
Abstract (Originalsprache)
VEGFR‐2 is a prominent therapeutic target in antitumor drug research to block tumor angiogenesis. This study focused on the synthesis and optimization of PROTACs based on the natural product rhein, resulting in the successful synthesis of 15 distinct molecules. In A549 cells, D9 exhibited remarkable antitumor efficacy with an IC 50 of 5.88±0.50 μM, which was 15‐fold higher compared to rhein (IC 50 =88.45±2.77 μM). An in‐depth study of the effect of D9 on the degradation of VEGFR‐2 revealed that D9 was able to induce the degradation of VEGFR‐2 in A549 cells in a time‐dependent manner. The observed effect was reversible, contingent upon the proteasome and ubiquitination system, and demonstrably linked to CRBN. Further experiments revealed that D9 induced apoptosis in A549 cells and led to cell cycle arrest in the G1 phase. Molecular docking simulations validated the binding mode of D9 to VEGFR, establishing the potential of D9 to bind to VEGFR‐2 in its natural state. In summary, this study confirms the feasibility of natural product‐bound PROTAC technology for the development of a new generation of VEGFR‐2 degraders, offering a novel trajectory for the future development of pharmacological agents targeting VEGFR‐2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Engineering Research Centre of Molecular Medicine of Ministry of Education, Key Laboratory of Fujian Molecular Medicine, Key Laboratory of Precision Medicine and Molecular Diagnosis of Fujian Universities, Key Laborator…
- Department of Pharmacy, Quanzhou Medical College, 362021, Quanzhou, China.
ORCID-Profile: Jieqing Liu
Förderung
- Fujian Provincial Industry-University Cooperation Project
- Quanzhou High-Level Talent Innovation and Entrepreneurship Project
- National Natural Science Foundation of China
Zitieren
APA
Zhang, Z., Xu, M., Shi, R., He, X., Wang, Y., Shao, Y., Huang, C., Zhang, F., Zhang, P., & Liu, J. (2024). Natural Compound‐Rhein and PROTACs Unleash Potent VEGFR‐2 Degraders. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202400753
Vancouver
Zhang Z, Xu M, Shi R, He X, Wang Y, Shao Y, et al. Natural Compound‐Rhein and PROTACs Unleash Potent VEGFR‐2 Degraders. Chemistry & Biodiversity. 2024. doi:10.1002/cbdv.202400753
BibTeX
@article{Zhang2024,
author = {Zhang, Ziqing and Xu, Meng and Shi, Ruling and He, Xinyi and Wang, Yan and Shao, Yongying and Huang, Caixia and Zhang, Fengyang and Zhang, Peixi and Liu, Jieqing},
title = {Natural Compound‐Rhein and PROTACs Unleash Potent VEGFR‐2 Degraders},
journal = {Chemistry & Biodiversity},
year = {2024},
doi = {10.1002/cbdv.202400753}
}
EUVIMED